Research
Research highlights
A growing body of scientific research investigating joint comfort, cartilage protection, inflammatory pathways, cellular activity and safety - for formulators, regulatory teams and healthcare professionals.
1
Human clinical trial
3
Pre-clinical studies
2
Peer-reviewed papers
1
Granted Indian patent
Explore the evidence
Four evidence pillars
Pre-clinical research
Cellular and animal studies examining inflammatory cytokines, joint swelling, cartilage degradation and MMP activity.
Read more →
Clinical research
The 12-week randomized, double-blind, placebo-controlled trial in 100 adults with mild-to-moderate knee osteoarthritis.
Read more →
Additional functional properties
Water dispersibility, absorption, bioavailability and cellular antiproliferative activity.
Read more →
Safety & toxicology
Acute oral toxicity, clinical laboratory monitoring, vital-sign assessments and adverse-event reporting.
Read more →
Study index
Published & completed studies
| Year | Title | Design | N | Key outcome |
|---|---|---|---|---|
| 2025 | Safety & efficacy of Turmimax® BIO in mild-to-moderate knee OA | RDBPC clinical trial | 100 | Improved WOMAC, VAS, function & biomarkers over 84 days |
| 2023 | Antiproliferative & apoptosis-inducing mechanism on HeLa cells | In-vitro | - | Concentration-dependent inhibition, IC50 87.89 µg/mL |
| 2022 | Anti-inflammatory potential of Turmimax® BIO - in vivo & in vitro | Cellular + animal | 30+30 + assays | Reduced IL-8, IL-12, ear & paw oedema |
| - | Effect of Turmimax® BIO in MIA-induced osteoarthritis | Animal model | - | Reduced swelling, cartilage degradation & MMPs; supported COL2A1, aggrecan |
| - | Acute oral toxicological evaluation | Acute toxicity | - | No mortality or acute signs at 2,000 mg/kg body weight |